The Company has granted an aggregate of 7,000,000 stock options to eligible participants pursuant to the Company's stock option plan. About Theralase Technologies Inc.:Theralase is a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses. Forward-Looking StatementsThis news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/308758Source: Theralase Technologies Inc.